Skip to main content
Paul Maher

Paul Maher serves as a Vice Chair of Greenberg Traurig. He concentrates on corporate law, particularly cross-border public and private mergers and acquisitions. He advises a wide range of domestic and international clients in numerous sectors, including chemicals, pharmaceuticals, life sciences, financial services, information services, retail and communications.

Paul is highly recommended by both of the leading independent guides to the legal industry. In its 2020 edition, Chambers UK stated Paul offers clients "strategic and creative" nous in connection with international public and private M&A in a broad variety of sectors, with one client saying, "Paul is very commercial, offers good judgement of real risks and is an excellent negotiator of both technical and commercial points."

The Legal 500 UK highlighted that, 'Paul Maher is the best deal-making lawyer in the City' in its 2020 edition.

Concentrations

  • Chemicals, pharmaceuticals, biotechnology, agrochemicals
  • Entertainment / music industry
  • Communications
  • Banking

Expertise

Erfahrung

  • Advised Bracco Imaging S.p.A., an Italian manufacturer of agents and tracers used in diagnostic imaging, in the $450 million acquisition of Blue Earth Diagnostics Limited, a company which specializes in developing molecular imaging agents used in PET scans, from Syncona Portfolio Limited, subject to a $25 million closing adjustment.
  • Advised Paul Barry, the majority shareholder of Cambridge United Football Club Limited (CUFC), on his acquisition of all the remaining shares in CUFC to become the football club's sole shareholder.
  • Advised KIPCO in transaction related advice. The deal involved providing periodic strategic and English law contractual advice on the corporate aspects of a Middle East-based joint venture in which the client is the majority shareholder, including the corporate aspects associated with a material debt financing of the JV company.
  • Advised AstraZeneca AB on its agreement with Grünenthal to divest the European rights to Nexium for an upfront payment of $700 million with further sales-related and milestone payments of up to $90 million.
  • Advised AstraZeneca AB on its agreement with Grünenthal to divest the global rights to Vimovo in all markets excluding the United States and Japan for an upfront payment of $115 million and further payments up to another $17 million.
  • Advised Taiyo Nippon Sanso Corporation, a Japanese-based industrial gas producer, and its subsidiary Matheson Tri-Gas, in connection with its €5 billion acquisition of Praxair's European industrial gas business.
  • Advised of Rentokil Initial plc the world’s leading commercial pest control services provider on the worldwide acquisition of Cannon Hygiene business from OCS Group Limited.
  • Advised Smiths Group plc on the sale of Smiths Interconnect’s Microwave Telecoms business to Infinite Electronics Incfor US$112.5m.
  • Advised Rentokil Initial plc on its joint venture agreement with Haniel & Cie. Holding Company which created a leading provider of workwear and hygiene services in Europe with combined revenues of c. €1.1bn.
  • Advised Rentokil Initial plc on its joint venture with PCI Pest Control Pvt. Ltd., creating the largest provider of pest control services and products in India.
  • Advised AstraZeneca plc on the sale of its small molecule antibiotics business to Pfizer for US$725m.
  • Advised AB Volvo on the sale of its North American construction equipment rental business to Platinum Equity for $1.1bn.
  • Advised Rentokil Initial plc on the sale of its Initial Facilities business to Interserve plc for £250m.
  • Advised AB Volvo on the sale of its Volvo Aero aircraft engines business to GKN (Holdings) plc for £700m.
  • Advised AstraZeneca plc on its US$1.15bn (£740m) acquisition of Pearl Therapeutics, a privately held US company developing inhaled combination therapies for the treatment of respiratory diseases.
  • Advised Rentokil Initial plc on its sale of City Link Limited to BECAP12 Fund LP (Better Capital), a private equity investor.
  • Advised AstraZeneca plc on its agreement to sell its AstraTech business to Dentsply for $1.8bn.
  • Advised Smiths Group plc in relation to its joint venture with Analogic. 
  • Advised Healthcor, 3i and senior management of ApaTech Limited in its US$330m sale to global health care company Baxter International Inc.
  • Advised Dutch food company Vion in its purchase of a majority shareholding in J&J Tranfield. 
  • Advised AstraZeneca plc in connection with its equity investment in the AIM-listed Silence Therapeutics. 
  • Advised AstraZeneca plc and its subsidiary Cambridge Antibody Technology Limited in the disposal by CAT of its Humira® royalty stream to Royalty Pharma.
  • Advised shareholders of The Mergermarket Group on their agreement to sell the entire issued share capital of Pearson plc.
  • Advised Imperial Chemical Industries plc (ICI) on its agreement to sell its Uniqema manufacturing to Croda International plc.
  • Advised Bear Stearns and its subsidiary BSG Insurance Holdings on the acquisition of Minster Insurance Services from Groupama UK for an undisclosed sum. 
  • Advised senior management on the sale of Financial Dynamics to FTI Consulting Inc.
  • Advised Cambridge Antibody Technology Group plc on its recommended cash offer by AstraZeneca for its entire issued and to-be-issued share capital. 
  • Advised Etex SA on the disposal of its Thermalite division to Hanson.
  • Advised Danske Bank on its acquisition of Northern Bank and National Irish Bank from National Australia Bank. 
  • Advised Wittington Investments on its recommended offer for Selfridges plc. 
  • Advised ICI plc on the sale of the U.S., Canadian and European Vinamul Polymers business National Starch and Chemical (NSC) Company to Celanese. (NSC is a business unit of ICI.)
  • Advised GE on its recommended offer for Druck Holdings plc. 
  • Advised Cable & Wireless plc on its purchase of UK-based broadband service provider Bulldog Communications Limited. 
  • Advised Monsanto Company and its subsidiaries on the disposal of its European wheat and barley seed business to RGAT Genetique S.A.
  • Advised Cambridge Antibody Technology Group plc on its proposed takeover of Oxford GlycoSciences plc to be effected by way of a scheme of arraignment.

°Certain of the above representations were handled by Mr. Maher prior to his joining Greenberg Traurig, LLP.

  • In-house lawyer, Imperial Chemical Industries (ICI) PLC, 1984-1990

Anerkennung durch den Markt

  • Listed, IFLR 1000 United Kingdom, "Leading Lawyers" M&A, 2017-2020
  • Listed, Chambers UK Guide, Corporate/M&A, 2012-2020
  • Listed, Chambers Global, Corporate/M&A (UK), 2012-2019
  • Listed, The Legal 500 United Kingdom, Corporate and Commercial – M&A: Upper Mid-Market and Premium Deals, 2011-2017
  • Listed, Super Lawyers magazine, London Super Lawyers, 2013-2014
  • Member, Winning Team, M&A Deal of the Year (Over US$1 Billion), M&A Advisor Awards, 2013
  • Member, Winning Team, Consumer and Retail Products Deal of the Year (Over US$1 Billion), M&A Advisor Awards, 2013
  • Shortlisted, The Lawyer Awards, "Partner of the Year", 2010
  • Recipient, The Lawyer Awards, “Partner of the Year”, 2007
  • Listed, Management, ”The Lawyer’s Hot 100 Survey”, January 2003 and 2007 
  • Listed, UK Financial Times, one of the three most innovative lawyers, "Survey of Innovative Lawyers", June 2006 
  • Listed, PLC Which Lawyer?

Ausbildung

Akademische Ausbildung
  • LL.B., Bristol University
Zulassung
  • England & Wales
Sprache